Avalyn Pharma (AVLN) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.98

Estimate

-$0.56

Surprise

-73.5%

Score today

5.5/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Avalyn Pharma (AVLN) reported a wider loss than forecast — diluted EPS of -$0.98 against the -$0.56 estimate (a 73.5% shortfall).

• Morgan Stanley Maintains Overweight on Avalyn Pharma, Raises Price Target to $57 — benzinga, 2026-08-13
• Avalyn Pharma Q2 EPS $(0.65) Misses $(0.53) Estimate — benzinga, 2026-08-12

TrendMatrix currently rates AVLN Sell at 5.5/10; no pre/post engine snapshot brackets this report.

0 of the last 2 quarters beat the estimate; this quarter's -73.5% surprise compares with a -1326.0% four-quarter average. Next scheduled report: 2026-11-16.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$34.71

Price target

$52.91

Stop

$32.28

Upside to target

+52.4%

Reward-to-risk

4.5:1

Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.52B

P/E (fwd)

-18.0

52-week range

$24.15–$40.17

Off 52-week high

13.6%

RSI (14)

40

Volume vs avg

1.22×

Score today

5.5/10